GlassScriptPhysician profile
Reem Douidar
NPI 1609090851
$3,093.67
in general payments reported to CMS, 2019-2025
28 companies · $76.69 in 2025
The $76.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $640 · 2021: $1,043 · 2022: $570 · 2023: $344 · 2024: $13.40 · 2025: $76.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.50 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $413.54 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $326.69 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $296.49 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $284.10 | 2019-2023 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.19 | 2019-2023 | Synjardy, Tradjenta, Jardiance |
| Amarin Pharma, INC. | $211.07 | 2019-2021 | |
| Pfizer INC. | $180.60 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $152.78 | 2019-2021 | |
| Abbvie INC. | $135.58 | 2021-2023 | Ubrelvy |
| Abbott Laboratories | $108.37 | 2021-2022 | |
| Nevro Corp. | $98.38 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.16 | 2020-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $66.67 | 2020-2022 | |
| Boston Scientific Corporation | $56.32 | 2019-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $55.21 | 2020-2024 | Shingrix, Arexvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $42.46 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.30 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $39.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.96 | 2022-2023 | |
| Lifescan, INC. | $27.16 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.44 | 2020-2022 | |
| Esperion Therapeutics, INC. | $24.67 | 2020 | |
| Cequr Corporation | $21.91 | 2023 | Cequr Simplicity |
| Alnylam Pharmaceuticals INC. | $21.89 | 2025 | Givlaari |
| Exact Sciences Corporation | $19.97 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $17.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Douidar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.